Abstract:Background According to prescribing information for Myrtol standardized enteric-coated soft capsules, the medicine should be taken on an empty stomach. Some patients may experience stomach discomfort after oral administration in fasted state and would prefer to take the medicine after a meal. However, there is no literature addressing the effect of meal on absorption of this drug; therefore, it is desirable to explore the feasibility of taking the capsule after a meal from pharmacokinetic perspective. Methods A gas chromatography coupled with triple quadruples mass spectrometry assay was established and validated for determining plasma concentrations of eucalyptol, a target component of Myrtol standardized capsules. A self-control clinical study was carried out in healthy male volunteers in fasted and fed states after a single oral dose of 300 mg capsules. Comparison of pharmacokinetic parameters in the two phases and bioequivalence evaluation were performed. Results The specificity, sensitivity, accuracy, and precision of the assay satisfied the requirements for biopharmaceutical analysis. Pharmacokinetic parameters of eucalyptol (fasted vs fed) were as follows: maximal plasma concentrations (Cmax) (167.60±114.69 vs 518.89±314.47 ng·mL−1), time of maximum concentration (Tmax) (3.7±1.1 vs 4.8±0.7 h), elimination half-life (T1/2) (3.2±1.4 vs 2.6±0.7 h), area under the plasma concentration–time curve (AUC0–t) (584.91±369.90 vs 1,271.61±605.82 ng·h·mL−1), and AUC0–∞ (690.36±467.26 vs 1,458.02±720.21 ng·h·mL−1). There was statistically significant difference in Cmax, AUC0–t, and AUC0–∞ between the two dosing methods (P<0.05). Pharmacokinetic parameters of eucalyptol given in fasted state in Chinese were comparable to those in Germany population. The 90% confidence intervals for the ratio of Cmax (18.4%~64.7%), AUC0–t (28.9%~68.5%), and AUC0–∞ (31.1%~68.4%) values for the test (fasted) and reference (fed) were beyond the Food and Drug Administration’s acceptable range of 80%~125%. In addition, significant difference was obtained in Tmax (P<0.05). Conclusion Compared with dosing at fasted state, taking Myrtol standardized capsules after a meal achieves a delayed absorption rate and an increased absorption extent. The two dosing methods were not bioequivalent in this small study and, thus, not interchangeable. Patient preference and pharmacokinetic food–drug interaction issue should be balanced. Further clinical study is necessary to explore the clinical outcome of oral administration of Myrtol standardized capsules after or with meal.

Effect of Food on the Pharmacokinetics of Rosuvastatin after Administration of a Single Oral Dose in Dogs

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies

Is It Appropriate Regarding Patient Preference to Take Myrtol Standardized Enteric-Coated Soft Capsules after a Meal Rather Than at Fasted State? A Food–drug Pharmacokinetic Interaction Study in Healthy Chinese Volunteers

Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.

Effects of Different Doses of Rosuvastatin on High-sensitivity C-reactive Protein(hs-CRP) and Interleukin-6 (IL-6) in Patients with Acute Coronary Syndrome.

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1

The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed‐Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects

The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule

The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity

Pharmacokinetics and Bioequivalence of Two Formulations of Rosuvastatin Following Single‐dose Administration in Healthy Chinese Subjects Under Fasted and Fed Conditions

Effect of Food on Pharmacokinetics and Pharmacodynamics of Fenofibric Acid aftera Single Oral Dose of Fenofibrate Sustained-Release Capsule

Effects of Food on Absorption of Ozagrel after Oral Administration in Healthy Volunteers

Evaluation of Quercetin's Bioenhancing Effect on Oral Pharmacokinetics of Rosuvastatin in Wistar Rats Using RP-HPLC Method

Study on Pharmacokinetics-Pharmacodynamics of Xinning Extended Action Tablet on Dogs

Comparison of the Pharmacokinetics of a Fixed‐Dose Combination of Rosuvastatin/Metformin Sustained‐Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects

Effect of Green Tea and (-)-Epigallocatechin Gallate on the Pharmacokinetics of Rosuvastatin

Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults

Impact of 10 Mg Rosuvastatin Daily or Alternate-Day on Lipid Profile and Inflammatory Markers

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers